4.74
前日終値:
$4.79
開ける:
$4.79
24時間の取引高:
401.04K
Relative Volume:
0.88
時価総額:
$279.35M
収益:
$192.64M
当期純損益:
$2.51M
株価収益率:
90.46
EPS:
0.0524
ネットキャッシュフロー:
$12.42M
1週間 パフォーマンス:
-0.84%
1か月 パフォーマンス:
+2.82%
6か月 パフォーマンス:
+7.73%
1年 パフォーマンス:
-22.93%
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
名前
Vanda Pharmaceuticals Inc
セクター
電話
202-734-3400
住所
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
VNDA
Vanda Pharmaceuticals Inc
|
4.74 | 282.30M | 192.64M | 2.51M | 12.42M | 0.0524 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-31 | 開始されました | H.C. Wainwright | Buy |
2024-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
2022-02-25 | ダウングレード | Jefferies | Buy → Hold |
2021-05-12 | 開始されました | BofA Securities | Buy |
2021-01-14 | ダウングレード | Citigroup | Buy → Neutral |
2020-10-29 | アップグレード | Citigroup | Neutral → Buy |
2020-06-09 | ダウングレード | Citigroup | Buy → Neutral |
2020-03-16 | ダウングレード | Oppenheimer | Perform → Underperform |
2020-03-12 | アップグレード | Citigroup | Neutral → Buy |
2019-11-07 | ダウングレード | Citigroup | Buy → Neutral |
2019-08-01 | アップグレード | Citigroup | Neutral → Buy |
2019-07-25 | ダウングレード | Stifel | Buy → Hold |
2018-12-11 | ダウングレード | Oppenheimer | Outperform → Perform |
2018-12-04 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
2018-12-04 | 繰り返されました | Jefferies | Buy |
2018-11-08 | 再開されました | Jefferies | Buy |
2018-09-21 | 再開されました | Oppenheimer | Outperform |
2018-05-23 | 開始されました | Citigroup | Buy |
2018-01-19 | 開始されました | Seaport Global Securities | Buy |
2017-09-14 | 繰り返されました | Piper Jaffray | Overweight |
2017-06-27 | 再開されました | Piper Jaffray | Overweight |
2017-05-26 | 開始されました | H.C. Wainwright | Buy |
2017-04-12 | 開始されました | Oppenheimer | Outperform |
2016-11-09 | 開始されました | Aegis Capital | Buy |
2016-10-06 | 再開されました | Jefferies | Buy |
すべてを表示
Vanda Pharmaceuticals Inc (VNDA) 最新ニュース
How does Vanda Pharmaceuticals Inc. generate profit in a changing economyBuild a diversified portfolio for stability - jammulinksnews.com
Should I hold or sell Vanda Pharmaceuticals Inc. stock in 2025Free Stock Market Query - jammulinksnews.com
Is Vanda Pharmaceuticals Inc. a growth stock or a value stockExceptional trading performance - jammulinksnews.com
Is Vanda Pharmaceuticals Inc. a good long term investmentRapid wealth accumulation - PrintWeekIndia
When is the best time to buy Vanda Pharmaceuticals Inc. stockPowerful profit generation - jammulinksnews.com
Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 - Barchart.com
Vanda Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing investment returns - jammulinksnews.com
What analysts say about Vanda Pharmaceuticals Inc. stockAccelerated capital growth - Autocar Professional
What drives Vanda Pharmaceuticals Inc. stock priceMassive profits - jammulinksnews.com
Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - beatles.ru
Vanda Pharmaceuticals’ Study on Trichostatin A: A Potential Game-Changer in Hematologic Malignancies - TipRanks
US FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Rejects Vanda Citizen Petitions - insights.citeline.com
Vanda Pharmaceuticals Inc.(NasdaqGM: VNDA) added to Russell 2000 Defensive Index - MarketScreener
Insider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharm - GuruFocus
DC Circ. Urged To Reject Approval For Braille-Free Drug Label - Law360
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - StreetInsider
Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S - MarketScreener
Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S - MarketScreener
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial E - GuruFocus
Vanda Pharmaceuticals (VNDA) Initiates First Human Trial for Ant - GuruFocus
Vanda's Breakthrough: First-Ever Personalized Treatment Trial Launches for Ultra-Rare CMT2S Disease - Stock Titan
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S | VNDA Stock News - GuruFocus
Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow
Vanda Approves Key Proposals at Annual Meeting - TipRanks
SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow
CLASS ACTION UPDATE for SPB, VNDA and ARA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Class Action Reminder Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire
Judge Favors Vanda But Seeks Deal Over Drug Approval - Law360
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting - PR Newswire
SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow
Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan
Justices Urged To Undo Denial Of Fast Track For Gastro Drug - Law360
Vanda Pharmaceuticals Inc (VNDA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):